Incretin-Based Treatment
PreclinicalSmall molecule
Incretin-Based Treatment is one of 29 small molecule programs targeting Physical Activity. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
42 competitors in Physical Activity
#DrugCompanyPhaseTrials
1Xolair
RocheApproved
Hemlibra
RocheApproved
Ranexa
MMenarini International Operations Luxembourg SA
Approved
Tnkase
RochePhase 3
Zometa
PfizerPhase 3
Activase
RochePhase 3
Striverdi Respimat
Boehringer IngelheimPhase 3
Spiriva
Boehringer IngelheimPhase 3
Aclidinium/formoterol
AstraZenecaApproved
Farxiga
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Incretin-Based Treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- JJohns Hopkins University